Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pbx995/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - AdAlta - AnaptysBio - Auspex Pharmaceuticals - BiOrion Technologies - Biogen Idec - Boehringer Ingelheim - Bristol-Myers Squibb - Celgeneration - Chong Kun Dang Pharmaceutical - Compugen - Corridor Pharmaceuticals - F. Hoffmann-La Roche - FibroGen - GenKyoTex - Gilead Sciences - GlaxoSmithKline - HanAll Biopharma - Histocell - ImmuneWorks - IntelGenx - InterMune - Kasiak Research - LTT Bio-Pharma - Lanthio Pharma - MSM Protein Technologies - MedImmune - Moerae Matrix - Pacific Therapeutics - Pharmaxis Limited - ProMetic Life Sciences For more information visit http://www.researchandmarkets.com/research/pbx995/idiopathic
BIIB: 325.13 (-10.67), GILD: 100.46 (-2.70), CGEN: 7.98 (-0.01), ASPX: 25.09 (+0.78), GSK: 41.92 (+0.62), BMY: 57.69 (-0.86)
Pacific Therapeutics Announces First Nine Months 2014 Financial Results
ACCESSWIRE - Tue Dec 02, 3:54PM CST
VANCOUVER, BC / ACCESSWIRE / December 2, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC: PCFTF) (1P3.F) (the "Company"
CEO Comments on Diagnostic Breakthrough for Pulmonary Fibrosis
ACCESSWIRE - Thu Nov 13, 7:35AM CST
VANCOUVER, BC, Canada / ACCESSWIRE / November 13, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"
Pacific Therapeutics CEO Comments on Big Pharmas Recent Interest In Acquiring Therapies to treat Fibrosis
ACCESSWIRE - Thu Nov 06, 7:32AM CST
VANCOUVER, BC, Canada / ACCESSWIRE / November 6, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"
Pacific Therapeutics Ltd. Issues Stock Options to Consultants
TheNewswire.ca - Wed Nov 05, 9:05AM CST
(via Thenewswire.ca)
Pacific Therapeutics Shares Article Explaining Rose Mcgowan's Kiss IPF Goodbye Campaign
ACCESSWIRE - Thu Oct 09, 7:31AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / October 9, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"
Pacific Therapeutics Annonuces Closing Of Non-Brokered Financing
ACCESSWIRE - Thu Oct 02, 7:40AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / October 2, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"
Pacific Therapeutics Announces Amendment to Non-Brokered Financing
ACCESSWIRE - Tue Sep 23, 7:31AM CDT
VANCOUVER, BC / ACCESSWIRE / September 23, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"
Pacific Therapeutics Shares Vancouver Sun Article Explaining Positive Impact of Cannabis on Child Having Epileptic Seizures and Need for New Formulations
ACCESSWIRE - Tue Sep 16, 7:06AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / September 16, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"
Update on PTL-202, a Treatment for Progressive Organ Scarring, a $1.1 Billion Opportunity
ACCESSWIRE - Thu Sep 04, 7:39AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / September 4, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"
ITMN: 73.89 (-0.02)
Vantage Wire Publishes Report on Pacific Therapeutics Partner Vodis Innovative Pharmaceuticals
ACCESSWIRE - Tue Sep 02, 3:32PM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / September 2, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"
Pacific Therapeutics Announces First Six Months 2014 Financial Results
ACCESSWIRE - Thu Aug 28, 5:13PM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 28, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTCBB: PCFTF) (Frankfurt: 1P3) (the "Company"
H.C. Wainwright Initiates Coverage of Pacific Therapeutics Partner Intelgenx with a Buy Recommendation
ACCESSWIRE - Fri Aug 15, 7:48AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 15, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"
Vodis Pharmaceuticals and Pacific Therapeutics Agree to Share Technologies to Deliver Cannabinoid Based Therapies
ACCESSWIRE - Tue Aug 05, 8:08AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 5, 2014 / Vodis Pharmaceuticals (CSE: VP) (the "Company"
Pacific Therapeutics Annonuces Non-Brokered Financing
ACCESSWIRE - Tue Aug 05, 7:33AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / August 5, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"
Proactive Investor Publishes Article on Pacific Therapeutics
ACCESSWIRE - Fri Jul 25, 7:32AM CDT
VANCOUVER, BC, Canada / ACCESSWIRE / July 25, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"